FDA Approves Ozempic in Chronic Kidney Disease
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in kidney function, or death from kidney or heart causes, in diabetic patients with chronic kidney disease.
An inquest in Cork has been told that a 66-year old woman died from "profound vomiting" brought on by the drug Ozempic, which ...
Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback